Metropolis Optimizes Cervical Cancer Screening: Combines Latest Technology with Cost Effective Reflex Strategy

Press Release

Hyderabad/Mumbai, January, 2015: Cervical cancer is one of the leading causes of cancer deaths among women in India, with approximately 1.32 lakh new cases of cervical cancer being diagnosed and about 74,000 deaths every year. Cervical cancer is predominantly caused by Human Papillomavirus (HPV), a common viral infection, accounting for most cancer deaths in Indian women and the second most common cancer in women worldwide. The good news is that cervical cancer is preventable and is curable if detected early.

January is observed as ‘Cervical Cancer’ awareness month globally and in an effort to spread awareness about cervical cancer screening, Metropolis Healthcare Ltd, “The Pathology Specialist” presents an analysis of screening data collated over two years. Metropolis Healthcare represents an ideal spectrum of Indian women as we receive samples from across the country.

Cervical Cancer and its symptoms

Cervical cancer occurs sequentially from abnormal cells which progresses to grow out of control. When symptoms appear, the disease is usually in its advanced stage. The most common symptoms include abnormal vaginal discharge, unexpected bleeding, bleeding after menopause and pain during sexual intercourse. Having multiple sexual partners, smoking and long term usage of contraceptive pills are the major reasons contributing to the disease.

Screening Recommendations

The latest recommendations from the American Cancer Society for cervical cancer screening are as below

  • All women should begin cervical cancer screening at age 21.
  • Women between the ages of 21 and 29 should have a Pap test every 3 years. They should not be tested for HPV unless it is needed after an abnormal Pap test result.
  • Women between the ages of 30 and 65 should have both a Pap test and an HPV test every 5 years. This is the preferred approach, but it is also OK to have a Pap test alone every 3 years.
  • Women over age 65 who have had regular screenings with normal results should not be screened for cervical cancer. Women who have been diagnosed with cervical pre-cancer should continue to be screened.

Screening Methods

Cervical cancer can be screened using different methods:

  • Conventional PAP: The Pap test can find early cell changes before they become cancerous. This aids in early treatment
  • Liquid based cytology (LBC) PAP Smear: An advanced technique that differs from conventional Pap in way of preparing cervical samples for examination in the laboratory. The biggest benefit of this test to women is that there is no uncertainty in test results or the need for a repeat sample.
  • HPV DNA Tests: The HPV (human papilloma virus) test finds certain infections that can lead to cell changes and cancer. HPV infections are very common, and most go away by themselves and don’t cause these problems. The HPV test may be used along with a Pap test, or to help doctors decide how to treat women who have an abnormal Pap test.

In order to understand & compare the effectiveness of two screening methods for Cancer, Metropolis shares the data on 12,603 samples processed from 2012 to 2013.

Total Samples

total samples



Total vs Positive

totals vs positives

Findings of the study:

  • In LBC preparations the detection rate was 4.22% whilst 1.30% was abnormal in conventional smears. Chances of missing abnormalities in conventional PAP are high if the sample collection is not done meticulously.
  • A total of 350 samples were found positive for abnormalities which accounts to 2.77% of all tested samples.
  • Out of the total 350 samples that were tested positive, the age wise break up is as below

age group percentage

In another study performed on 3,711 HPV DNA samples processed from 2011 to 2013, the HPV infection rate was about 10.34%. HPV genotype 16 and HPV genotype 18 is commonly associated with high risk of development of cervical cancer. Out of the 296 samples tested positive for HPV infection, 45% of the samples are associated with genotypes 16, followed by 15% of genotypes 18.

hpv genotypes

HPV DNA testing is used as a follow up to abnormal changes detected with Pap smear screening methodology. It detects the presence of oncogenic strains of HPV in cervical cells. HPV DNA testing in itself does not detect abnormal cell changes in the cervix as the Pap smear does. A woman who tests positive for HPV still requires a Pap smear to check for possible cervical abnormalities. Isolated HPV DNA testing doesn’t allow detection of cytological abnormality. Hence Metropolis offers co-testing which combines combining latest technology with cost effective reflex strategy that aids the physician in making treatment decisions and disease management.

metropolis-cervical-cancer-jan-2015Commenting on the results, Dr. Kirti Chadha (Divisional Head – Oncology, Group & Surgical Pathology, Mumbai) emphasized, “Cervical cancer can be prevented if diagnosed early before the abnormal cells become cancerous. In our experience we have noted that an LBC Pap coupled with an HPV DNA i.e. Molecular Pap done every 5 years yields excellent patient compliance and assists in optimal patient management. In addition, Metropolis is the only lab in the country to offer CISH and p16INK4a to help gynecologists identify patients for therapy vis a vis active follow up.”


At Metropolis, what we believe is what we say and what we say is what we do. Being empathetic to our customers and being committed to their needs is in our DNA. Metropolis has grown to harness a culture that is open, synergistic, progressive and scientific in nature.

We are the Pathology Specialists delivering over 15 million tests a year, catering to more than 10,000 Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants. With 33 years of experience in delivering accurate reports, Metropolis has earned the reputation of being India's most respected and only multinational chain of diagnostic centres with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius and Ghana. Driven to make a difference, our wide network includes 125 state-of-art Laboratories across India with over 800 collection centres, processing over 4500 varieties of tests and supported by an efficient team of more than 3500 people. Equipped with cutting edge technology, innovative work equipment, expansive logistics network and rigorous processes, Metropolis ensures and delivers precision and accuracy in every single test; each time, every time.

In the last 10 years, Metropolis has expanded into new service lines like Clinical Trials, Hospital Lab Management, Home Health Services, Preventive Health Check-ups and Corporate & Wellness Solutions. Metropolis is at the forefront in adopting cutting edge technologies and services that contribute new revenue streams and has positioned the company on the pedestal it is today.

Today, we are one of the few laboratories that has received the CAP (College of American Pathologists), accreditation, the global gold standard in Laboratory Accreditation. 12 of our laboratories in India has received the NABL Accreditation (National Accreditation Board for testing and Calibration Laboratories). In addition, the central laboratory in Mumbai also adheres to CLIA (Clinical Laboratory Improvement Amendments) program and also follows the guidelines laid by GCP and GLP. Our unit in South Africa is accredited by SANAS (South African National Accreditation System is the only accreditation body approved by South African Government).

Metropolis has been awarded numerous accolades like the ‘Best Diagnostic Company of the year’ by Modern Medicare in 2006 and ‘Best Diagnostic Company of the Year’ in 2010 by Frost & Sullivan. Metropolis was also bestowed with ‘Best IT Integration in Customer Service Management’ at the e-Health World Expo 2011. Metropolis was also honoured with the ‘Quality Brand Award’ by NEHRDO in 2012. Metropolis won the ‘CMO Asia Award’ for Best IT practices in Healthcare in 2012. Metropolis Healthcare also bagged the Emerging Companies Excellence Award in the Productive Employment category hosted by Yes Bank and Business Today.

Metropolis Healthcare is led by Ameera Shah, Managing Director & CEO. An International & National Award winners, she was conferred with ‘The Young entrepreneur of the Year Award’ by GE in 2006 and ‘The Young Achiever of the Year Award’ at the CMO Asia Awards in 2011. She was also the recipient of the prestigious ‘Young Entrepreneur of the Year Award’ in 2011 organised by Entrepreneur India and Bloomberg. She has been honoured with ‘Women Leadership award’ at the World Women Leadership and Congress awards 2014. Recently she has been chosen as one of the most respected leaders under 40 years by Economic Times & Spencer Stuart (2014).

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Press Releases and tagged . Volume: .

Post a Comment

You must be logged in to post a comment.